AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Entry into a Material Definitive Agreement

AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01

Story continues below

This report contains forward-looking statements, including, but not limited to, statements related to Avadel's sale of its pediatric assets to Cerecor and Avadel's ability to consummate the closing of such transaction, including the satisfaction of certain closing conditions including the delivery of certain third-party guarantees and consents, Avadel's ability to develop four new pediatric products under its license and development agreement with Cerecor, Avadel's business strategy and development plans, expected financial performance in future periods, expected timing of clinical, regulatory and commercial events, and other statements that are not historical facts. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Although we believe that the forward-looking statements contained in this report are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks and there can be no assurance that actual results will not differ materially from the expectations expressed in the forward-looking statements contained in this report. We undertake no obligation to update these forward-looking statements as a result of new information, future events or otherwise. You should not place undue reliance on these forward-looking statements. Except as required by law, we specifically disclaim any obligation to update such forward-looking statements.

EX-99.1 2 ex99_1forf8k02122018.htm EXHIBIT 99.1 Exhibit 99.1   Avadel Pharmaceuticals Announces Divestiture of Pediatric Business Cerecor to acquire Avadel’s pediatric assets Enters into license agreement to develop four LiquiTime™ or Micropump® products Dublin,…
To view the full exhibit click here

An ad to help with our costs